These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 16794438)

  • 1. The burden of age-related macular degeneration: a value-based analysis.
    Brown MM; Brown GC; Sharma S; Stein JD; Roth Z; Campanella J; Beauchamp GR
    Curr Opin Ophthalmol; 2006 Jun; 17(3):257-66. PubMed ID: 16794438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The burden of age-related macular degeneration: a value-based medicine analysis.
    Brown GC; Brown MM; Sharma S; Stein JD; Roth Z; Campanella J; Beauchamp GR
    Trans Am Ophthalmol Soc; 2005; 103():173-84; discussion 184-6. PubMed ID: 17057801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-related macular degeneration: economic burden and value-based medicine analysis.
    Brown MM; Brown GC; Stein JD; Roth Z; Campanella J; Beauchamp GR
    Can J Ophthalmol; 2005 Jun; 40(3):277-87. PubMed ID: 15947797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-related macular degeneration: the costs to society and the patient.
    Gupta OP; Brown GC; Brown MM
    Curr Opin Ophthalmol; 2007 May; 18(3):201-5. PubMed ID: 17435426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life and health economic assessments of age-related macular degeneration.
    Covert D; Berdeaux G; Mitchell J; Bradley C; Barnes R
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S20-5. PubMed ID: 17240252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of treatment of age-related macular degeneration: a review.
    Kymes Steven M
    Minerva Med; 2009 Feb; 100(1):69-78. PubMed ID: 19277005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value-based medicine and interventions for macular degeneration.
    Brown MM; Brown GC; Brown H
    Curr Opin Ophthalmol; 2007 May; 18(3):194-200. PubMed ID: 17435425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
    Brown MM; Brown GC; Brown HC; Peet J
    Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computerized model of cost-utility analysis for treatment of age-related macular degeneration.
    Fletcher EC; Lade RJ; Adewoyin T; Chong NV
    Ophthalmology; 2008 Dec; 115(12):2192-8. PubMed ID: 18930556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoeconomics and macular degeneration.
    Brown GC; Brown MM; Brown H; Godshalk AN
    Curr Opin Ophthalmol; 2007 May; 18(3):206-11. PubMed ID: 17435427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on utilities and cost-utility analyses.
    Hollands H; Sharma S
    Curr Opin Ophthalmol; 2006 Jun; 17(3):223-7. PubMed ID: 16794433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost of vision for vitreoretinal interventions.
    Smiddy WE
    Curr Opin Ophthalmol; 2008 May; 19(3):195-201. PubMed ID: 18408493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Implantable Miniature Telescope for macular degeneration.
    Lane SS; Kuppermann BD
    Curr Opin Ophthalmol; 2006 Feb; 17(1):94-8. PubMed ID: 16436930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eye-related medicare costs for patients with age-related macular degeneration from 1995 to 1999.
    Coleman AL; Yu F
    Ophthalmology; 2008 Jan; 115(1):18-25. PubMed ID: 17572499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The comparative effectiveness and cost-effectiveness of vitreoretinal interventions.
    Brown MM; Brown GC; Brown HC; Irwin B; Brown KS
    Curr Opin Ophthalmol; 2008 May; 19(3):202-7. PubMed ID: 18408494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The depletion of susceptibles effect in the assessment of burden-of-illness: the example of age-related macular degeneration in the community-dwelling elderly population of Quebec.
    Tournier M; Moride Y; Lesk M; Ducruet T; Rochon S
    Can J Clin Pharmacol; 2008; 15(1):e22-35. PubMed ID: 18579928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is significant relevant? Validity and patient benefit of randomized controlled clinical trials on age-related macular degeneration.
    Joussen AM; Lehmacher W; Hilgers RD; Kirchhof B
    Surv Ophthalmol; 2007; 52(3):266-78. PubMed ID: 17472802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration].
    Neubauer AS; Holz FG; Schrader W; Back EI; Kühn T; Hirneiss C; Kampik A
    Klin Monbl Augenheilkd; 2007 Sep; 224(9):727-32. PubMed ID: 17846963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New insights into the underestimated impairment of quality of life in age-related macular degeneration - a review of the literature].
    Meyer-Ruesenberg B; Richard G
    Klin Monbl Augenheilkd; 2010 Aug; 227(8):646-52. PubMed ID: 20449793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs and quality of life of multiple sclerosis in Switzerland.
    Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.